Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Santhera Pharmaceuticals Holding AG    SANN   CH0027148649

SANTHERA PHARMACEUTICALS HOLDING AG

(SANN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société SANTHERA PHARMACEUTICALS HOLDING AG
11/26SANTHERA PHARMACEUTICALS : Completes Capital Increase for Financing Arrangements
AQ
11/25SANTHERA PHARMACEUTICALS : Completes Capital Increase for Financing Arrangements
PU
11/25SANTHERA PHARMACEUTICALS : Completes Capital Increase for Financing Arrangements
AQ
11/25SANTHERA PHARMACEUTICALS : Completes Capital Increase for Financing Arrangements
AQ
11/25Santhera Completes Capital Increase for Financing Arrangements
GL
11/17SANTHERA PHARMACEUTICALS : ReveraGen Receives $3.3 Million NIH Commercialization..
PU
11/17SANTHERA PHARMACEUTICALS : ReveraGen Receives $3.3 Million NIH Commercialization..
PU
11/17SANTHERA PHARMACEUTICALS : ReveraGen Receives $3.3 Million NIH Commercialization..
AQ
11/10SANTHERA PHARMACEUTICALS : to Present at Jefferies Virtual London Healthcare Con..
PU
11/10SANTHERA PHARMACEUTICALS : to Present at Jefferies Virtual London Healthcare Con..
AQ
11/10SANTHERA PHARMACEUTICALS : to Present at Jefferies Virtual London Healthcare Con..
AQ
11/10Santhera to Present at Jefferies Virtual London Healthcare Conference
GL
11/02SANTHERA PHARMACEUTICALS : Implements Reorganization and Secures Financing to Ad..
AQ
11/02SANTHERA PHARMACEUTICALS : Implements Reorganization and Secures Financing to Ad..
AQ
11/02Santhera Implements Reorganization and Secures Financing to Advance Vamorolon..
GL
10/23SANTHERA PHARMACEUTICALS : Completes Capital Increase for Financing Arrangements
AQ
10/22SANTHERA PHARMACEUTICALS : Completes Capital Increase for Financing Arrangements
PU
10/22SANTHERA PHARMACEUTICALS : Completes Capital Increase for Financing Arrangements
AQ
10/22SANTHERA PHARMACEUTICALS : Completes Capital Increase for Financing Arrangements
AQ
10/22Santhera Completes Capital Increase for Financing Arrangements
GL
10/06SANTHERA PHARMACEUTICALS : to Discontinue Phase 3 SIDEROS Study and Development ..
PU
10/06SANTHERA PHARMACEUTICALS : to Discontinue Phase 3 SIDEROS Study and Development ..
AQ
10/06SANTHERA PHARMACEUTICALS : to Discontinue Phase 3 SIDEROS Study and Development ..
AQ
10/06Santhera to Discontinue Phase 3 SIDEROS Study and Development of Puldysa® in ..
GL
09/23SANTHERA PHARMACEUTICALS : Announces Publication of Long-Term Clinical Data with..
AQ
09/22SANTHERA PHARMACEUTICALS : Announces Publication of Long-Term Clinical Data with..
PU
09/22SANTHERA PHARMACEUTICALS : Announces Publication of Long-Term Clinical Data with..
AQ
09/22Santhera Announces Publication of Long-Term Clinical Data with Vamorolone in ..
GL
09/15SANTHERA PHARMACEUTICALS : Announces Publication on Molecular Distinctions of Va..
AQ
09/14SANTHERA PHARMACEUTICALS : Announces Full Enrollment of ReveraGen's Pivotal VISI..
AQ
09/14SANTHERA PHARMACEUTICALS : Announces Publication on Molecular Distinctions of Va..
AQ
09/14Santhera Announces Publication on Molecular Distinctions of Vamorolone Compar..
GL
09/11SANTHERA PHARMACEUTICALS : Announces Full Enrollment of ReveraGen's Pivotal VISI..
PU
09/11SANTHERA PHARMACEUTICALS : Announces Full Enrollment of ReveraGen's Pivotal VISI..
AQ
09/11Santhera Announces Full Enrollment of ReveraGen's Pivotal VISION-DMD Study wi..
GL
09/08SANTHERA PHARMACEUTICALS : Announces Financial Results for the First Half-Year 2..
PU
09/08SANTHERA PHARMACEUTICALS : Announces Financial Results for the First Half-Year 2..
AQ
09/02Santhera Exercises Option to Obtain Worldwide Rights to Vamorolone in Duchenn..
GL
08/11SANTHERA PHARMACEUTICALS : vollzieht Kapitalerhöhung für Finanzierungsvereinbaru..
PU
08/11Santhera Completes Capital Increase for Financing Arrangements
GL
07/20Santhera to Join SIX Swiss Exchange Life Science Industry Indices
GL
07/14Santhera Closes First Tranche of Financing Transaction
GL
06/24SANTHERA PHARMACEUTICALS : UK's MHRA renews EAMS Scientific Opinion for Santhera..
AQ
06/23UK's MHRA renews EAMS Scientific Opinion for Santhera's Idebenone in Duchenne..
GL
06/16Santhera Completes Capital Increase for Financing Arrangements
GL
06/04Santhera Receives Financing Commitment of up to CHF 20 Million from Fund Mana..
GL
06/03SANTHERA PHARMACEUTICALS : Announces Completion of ReveraGen's Long-Term Extensi..
AQ
06/02Santhera Announces Completion of ReveraGen's Long-Term Extension Study with V..
GL
05/29Santhera Provides Update on the Ongoing Regulatory Review of Puldysa® (Ideben..
GL
05/21SANTHERA PHARMACEUTICALS : Completes Enrollment of Phase 3 SIDEROS Study with Pu..
AQ
05/20Santhera Completes Enrollment of Phase 3 SIDEROS Study with Puldysa® (Idebeno..
GL
05/06Santhera Signs Agreements in Gene Therapy Research for Congenital Muscular Dy..
GL
04/27SANTHERA PHARMACEUTICALS : and Cold Spring Harbor Laboratory to Investigate Lono..
AQ
04/23SANTHERA PHARMACEUTICALS : Shareholders approve all Board Proposals at Today's A..
AQ
04/22Santhera's Shareholders Approve all Board Proposals at Today's Annual General..
GL
04/08Santhera Completes Capital Increase to Create Shares for IRIS
GL
04/08Santhera Enters into Equity-linked Financing to Provide up to CHF 12 million ..
GL
03/24SANTHERA PHARMACEUTICALS : Reports 2019 Annual Results and Highlights Pipeline P..
AQ
01/27Santhera Reports Net Revenues 2019 and Highlights Pipeline Progress
GL
01/24Santhera Appoints New Chief Financial Officer
GL
2019Santhera Announces Publication of Long-term Idebenone Data from SYROS Study i..
GL
2019Santhera Appoints New Chief Executive Officer
GL
2019Vamorolone Designated Promising Innovative Medicine (PIM) for Treatment of Du..
GL
2019Santhera Announces Presentation by ReveraGen of Positive 18-Month Data with V..
GL
2019Santhera to Present Long-Term Data with Puldysa® (Idebenone) in Duchenne Musc..
GL
2019Santhera Announces Publication of Phase I Clinical Data with POL6014 in Journ..
GL
2019Santhera Announces Financial Results for the First Half-Year 2019
GL
2019Santhera Announces Publication by ReveraGen of Positive Phase IIa-Extension S..
GL
2019Santhera Announces Closing of Licensing Transaction with Chiesi Group for Rax..
GL
2019SANTHERA PHARMACEUTICALS : EMA Validates Santhera's Marketing Authorization Appl..
PU
2019SANTHERA PHARMACEUTICALS : UK's MHRA renews EAMS Scientific Opinion for Santhera..
PU
2019SANTHERA PHARMACEUTICALS : Shareholders Approve all Board Proposals at Today's A..
PU
2019SANTHERA PHARMACEUTICALS : Santhera's Shareholders Approve all Board Proposals a..
GL
2019SANTHERA PHARMACEUTICALS : Submits Marketing Authorization Application to the Eu..
GL
2019SANTHERA PHARMACEUTICALS : Enters into License Agreement with Chiesi Group for R..
GL
1  2  3  4  5Next
Upcoming event on SANTHERA PHARMACEUTICALS HOLDING AG